Kardigan (KARD) investor relations material

Executive summary

• Clinical-stage precision therapeutics company advancing three late-stage cardiovascular programs—Danicamtiv, Ataciguat, and Tonlamarsen—targeting diseases with no approved therapies.

• Initiated Phase 3 KINSHIP-DCM, dosed first patient in Phase 2b KARDINAL-ASH, and continued Phase 2b KATALYST-AV enrollment.

• Completed IPO in June 2026, raising $422.4 million in net proceeds and $460 million in gross proceeds; cash, cash equivalents, and investments totaled $660.7 million as of June 30, 2026.

• Operating losses continue to increase due to expanded R&D and G&A expenses, with an accumulated deficit of $453.4 million as of June 30, 2026.

Financial highlights

• Net loss for Q2 2026 was $116.2 million, up from $57.4 million in Q2 2025; net loss for the six months ended June 30, 2026 was $172.3 million.

• Research and development expenses rose to $56.4 million for Q2 2026, driven by increased clinical activity and headcount.

• General and administrative expenses decreased to $18.9 million in Q2 2026 due to the absence of prior-year one-time compensation.

• Change in fair value of contingent milestone liabilities was $43.5 million in Q2 2026, reflecting increased probability of milestone achievement post-IPO.

• Interest income increased to $2.8 million in Q2 2026, reflecting higher cash balances post-IPO.

Outlook and guidance

• Existing cash, cash equivalents, and investments expected to fund operations for at least the next 12 months.

• Multiple clinical milestones and topline data from Danicamtiv, Ataciguat, and Tonlamarsen expected in the first half of 2027.

• No revenue expected from product sales for several years; future funding needs anticipated as clinical programs advance.